News NICE rejects head and neck cancer drug once again NICE rejects German Merck's Erbitux, unsure of effectiveness.
Cancer FDA accepts Keytruda head and neck cancer filing Merck's PD-1 inhibitor Keytruda (pembrolizumab) has been accepted for priority review by the FDA in another new setting, head and neck cancer.
R&D Precision medicine, NGS, and the quantum leap in biomarkers In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
